Boston Scientific Sees Unusually High Options Volume (NYSE:BSX)

Key Points

• Boston Scientific experienced a significant rise in options trading, with a 184% increase in call options volume, totaling 30,436 contracts on Tuesday.
• Insider trading highlighted a 58.23% drop in ownership for Director Yoshiaki Fujimori and a 21.90% reduction for EVP Joseph Michael Fitzgerald, with insiders selling a total of 174,214 shares recently.
• Boston Scientific's stock has a market cap of $146.65 billion, with a recent earnings report showing revenue growth of 22.8% year-over-year and an EPS of $0.75, surpassing analyst expectations.

Boston Scientific Corporation (NYSE:BSX - Get Free Report) saw unusually large options trading activity on Tuesday. Investors acquired 30,436 call options on the company. This is an increase of 184% compared to the average daily volume of 10,711 call options.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director Yoshiaki Fujimori sold 2,901 shares of the business's stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the transaction, the director directly owned 2,081 shares of the company's stock, valued at approximately $222,646.19. The trade was a 58.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares of the company's stock, valued at approximately $18,659,923.46. This represents a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 174,214 shares of company stock valued at $18,397,457. Insiders own 0.50% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. FWL Investment Management LLC acquired a new position in Boston Scientific during the second quarter worth $26,000. Sound Income Strategies LLC boosted its holdings in Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider's stock worth $27,000 after purchasing an additional 120 shares during the last quarter. 1248 Management LLC acquired a new position in Boston Scientific during the first quarter worth $26,000. Y.D. More Investments Ltd acquired a new position in Boston Scientific during the first quarter worth $27,000. Finally, Investment Management Corp VA ADV acquired a new stake in Boston Scientific in the fourth quarter valued at $25,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Stock Performance

Shares of BSX opened at $98.97 on Wednesday. Boston Scientific has a 12 month low of $80.64 and a 12 month high of $109.50. The firm has a fifty day simple moving average of $104.71 and a 200 day simple moving average of $102.22. The stock has a market capitalization of $146.65 billion, a price-to-earnings ratio of 58.91, a PEG ratio of 2.40 and a beta of 0.65. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business had revenue of $5.06 billion during the quarter, compared to analysts' expectations of $4.89 billion. During the same quarter in the prior year, the company posted $0.62 earnings per share. The firm's revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Research analysts forecast that Boston Scientific will post 2.85 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on BSX shares. Needham & Company LLC reissued a "buy" rating and set a $121.00 price target on shares of Boston Scientific in a research note on Thursday, September 11th. Raymond James Financial boosted their price target on shares of Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a research note on Thursday, July 24th. Royal Bank Of Canada reissued an "outperform" rating on shares of Boston Scientific in a research note on Thursday, July 24th. Oppenheimer raised shares of Boston Scientific from a "market perform" rating to an "outperform" rating and boosted their price target for the stock from $118.00 to $125.00 in a research note on Monday, September 8th. Finally, Leerink Partners started coverage on shares of Boston Scientific in a research note on Monday, June 16th. They set an "outperform" rating and a $118.00 price target for the company. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $118.04.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.